Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Larotrectinib Success Underscores Need for NGS to Detect TRK Fusion-Positive Cancers

September 4th 2019

Alexander Drilon, MD, provides insight into his study on the role of larotrectinib in the treatment of patients with TRK fusions and brain metastases or those with primary CNS disease.

Expert Explains USPSTF Update of BRCA Screening Guidelines

August 29th 2019

Carol Mangione, MD, MSPH, shares insight on the specifics of the recommendations related to BRCA-mutation testing and how the USPSTF hopes these suggestions will impact patient outcomes.

Oncology Fellow Stresses Integrity in the Lab and Clinic

August 28th 2019

Research forms the backbone of medical knowledge, and research integrity is a crucial responsibility of any scientist.

Broader NGS Use in Oncology Hinges on Payers, Access, and Education

August 16th 2019

Using up-front, broadpanel genomic tests that include hundreds of genes can save money and, in some cases, improve outcomes compared with other diagnostic approaches, especially in lung cancer but also increasingly in breast, colorectal, skin, and other cancers.

Key Takeaway 6: Role of Immunotherapy in R/R mHCC

August 15th 2019

Key Takeaway 5: High AFP is a Biomarker for Ramucirumab

August 15th 2019

Key Takeaway 4: Second-Line Regorafenib After TKI in HCC

August 15th 2019

Key Takeaway 3: Role of Frontline I/O Still Pending

August 15th 2019

Key Takeaway 2: Initial Systemic Therapy in HCC

August 15th 2019

Key Takeaway 1: Multidisciplinary Management of HCC

August 15th 2019

Dr. Papadimitrakopoulou on Implications of the NILE Trial in NSCLC

August 6th 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the implications of the NILE trial in non–small cell lung cancer (NSCLC).

cfDNA Assay Emerges as Viable Option for MSI Detection

August 6th 2019

Cell-free DNA-based detection of microsatellite instability status was found to be highly concordant with tissue-based MSI testing.

Expert Advocates Universal Genetic Testing in Breast Cancer

August 5th 2019

Although research findings have established many applications for genetic information in breast cancer, not enough patients are being tested for the risk of germline mutations and new strategies are needed to broaden the clinical application of genomic advancements.

CMS Should Broaden Coverage for Germline Mutation Testing

July 31st 2019

Sometimes referred to as massively parallel sequencing, next-generation sequencing evaluates millions of DNA sequences simultaneously, representing a true revolution compared with traditional, labor-intensive methods in which far less DNA could be sequenced at once.

The Future of Managing Gynecologic Cancer

July 30th 2019

Standard Frontline Therapy for Endometrial Cancer

July 30th 2019

Updates in Testing Endometrial Cancer Biomarkers

July 30th 2019

Frontline Therapies for Metastatic Cervical Cancer

July 30th 2019

Cervical Cancer: Staging and Minimally Invasive Surgery

July 30th 2019

PARP Inhibitor Mechanisms of Resistance

July 30th 2019